JP2009523459A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009523459A5 JP2009523459A5 JP2008551863A JP2008551863A JP2009523459A5 JP 2009523459 A5 JP2009523459 A5 JP 2009523459A5 JP 2008551863 A JP2008551863 A JP 2008551863A JP 2008551863 A JP2008551863 A JP 2008551863A JP 2009523459 A5 JP2009523459 A5 JP 2009523459A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- recombinant fusion
- variable domain
- antibody
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims 65
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims 65
- 108090000765 processed proteins & peptides Proteins 0.000 claims 16
- 229920001184 polypeptide Polymers 0.000 claims 15
- 102000004196 processed proteins & peptides Human genes 0.000 claims 15
- 150000001413 amino acids Chemical class 0.000 claims 13
- 108060003951 Immunoglobulin Proteins 0.000 claims 12
- 102000018358 immunoglobulin Human genes 0.000 claims 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 claims 7
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 claims 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 7
- 125000003580 L-valyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(C([H])([H])[H])(C([H])([H])[H])[H] 0.000 claims 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 4
- 239000003102 growth factor Substances 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 102000005962 receptors Human genes 0.000 claims 4
- 108020003175 receptors Proteins 0.000 claims 4
- 125000003338 L-glutaminyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C(=O)N([H])[H] 0.000 claims 3
- 125000001176 L-lysyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C([H])([H])C(N([H])[H])([H])[H] 0.000 claims 3
- WQKAQKZRDIZYNV-VZFHVOOUSA-N Ala-Ser-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O WQKAQKZRDIZYNV-VZFHVOOUSA-N 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- 102000005755 Intercellular Signaling Peptides and Proteins Human genes 0.000 claims 2
- 108010070716 Intercellular Signaling Peptides and Proteins Proteins 0.000 claims 2
- 125000000769 L-threonyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](O[H])(C([H])([H])[H])[H] 0.000 claims 2
- 241001529936 Murinae Species 0.000 claims 2
- 108091008874 T cell receptors Proteins 0.000 claims 2
- 108010092262 T-Cell Antigen Receptors Proteins 0.000 claims 2
- 102000000479 TCF Transcription Factors Human genes 0.000 claims 2
- 108010016283 TCF Transcription Factors Proteins 0.000 claims 2
- 102000019997 adhesion receptor Human genes 0.000 claims 2
- 210000004899 c-terminal region Anatomy 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 108010057085 cytokine receptors Proteins 0.000 claims 2
- 102000003675 cytokine receptors Human genes 0.000 claims 2
- 238000003745 diagnosis Methods 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 230000004927 fusion Effects 0.000 claims 2
- 230000002439 hemostatic effect Effects 0.000 claims 2
- 229940088597 hormone Drugs 0.000 claims 2
- 239000005556 hormone Substances 0.000 claims 2
- 108091008039 hormone receptors Proteins 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 241000282412 Homo Species 0.000 claims 1
- NZGTYCMLUGYMCV-XUXIUFHCSA-N Ile-Lys-Arg Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N NZGTYCMLUGYMCV-XUXIUFHCSA-N 0.000 claims 1
- OGOYMQWIWHGTGH-KZVJFYERSA-N Thr-Val-Ala Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(O)=O OGOYMQWIWHGTGH-KZVJFYERSA-N 0.000 claims 1
- XCTHZFGSVQBHBW-IUCAKERBSA-N Val-Leu Chemical compound CC(C)C[C@@H](C([O-])=O)NC(=O)[C@@H]([NH3+])C(C)C XCTHZFGSVQBHBW-IUCAKERBSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000000524 functional group Chemical group 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 229940072221 immunoglobulins Drugs 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
- 108010036320 valylleucine Proteins 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US76170806P | 2006-01-24 | 2006-01-24 | |
| PCT/GB2006/004559 WO2007066106A1 (en) | 2005-12-06 | 2006-12-05 | Ligands that have binding specificity for egfr and/or vegf and methods of use therefor |
| PCT/GB2007/000227 WO2007085814A1 (en) | 2006-01-24 | 2007-01-24 | Fusion proteins that contain natural junctions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009523459A JP2009523459A (ja) | 2009-06-25 |
| JP2009523459A5 true JP2009523459A5 (enExample) | 2010-03-11 |
Family
ID=38028503
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008551863A Pending JP2009523459A (ja) | 2006-01-24 | 2007-01-24 | 天然の連結部を含有する融合タンパク質 |
| JP2008551864A Pending JP2009523460A (ja) | 2006-01-24 | 2007-01-24 | Ｉｌ−４および／またはｉｌ−１３に結合するリガンド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008551864A Pending JP2009523460A (ja) | 2006-01-24 | 2007-01-24 | Ｉｌ−４および／またはｉｌ−１３に結合するリガンド |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US20110159003A1 (enExample) |
| EP (2) | EP2441838A3 (enExample) |
| JP (2) | JP2009523459A (enExample) |
| KR (1) | KR20080098382A (enExample) |
| CN (1) | CN101578298A (enExample) |
| AU (1) | AU2007209202A1 (enExample) |
| BR (1) | BRPI0710572A2 (enExample) |
| CA (1) | CA2636854A1 (enExample) |
| CR (1) | CR10179A (enExample) |
| EA (1) | EA200801515A1 (enExample) |
| IL (1) | IL192572A0 (enExample) |
| MA (1) | MA30175B1 (enExample) |
| NO (1) | NO20082942L (enExample) |
| TW (2) | TW200740843A (enExample) |
| WO (1) | WO2007085815A2 (enExample) |
| ZA (1) | ZA200806202B (enExample) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2532677A1 (en) | 2005-10-21 | 2012-12-12 | Novartis AG | Human antibodies against il13 and therapeutic uses |
| WO2009138413A1 (en) * | 2008-05-15 | 2009-11-19 | Domantis Limited | Single domain antibodies that bind il-13 |
| EP2016101A2 (en) * | 2006-05-09 | 2009-01-21 | Genentech, Inc. | Binding polypeptides with optimized scaffolds |
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| CA2698419C (en) * | 2007-09-07 | 2019-11-12 | Ablynx N.V. | Binding molecules with multiple binding sites, compositions comprising the same and uses thereof |
| EP2036980A1 (de) * | 2007-09-14 | 2009-03-18 | Gruber, Jens | Herabregulation der Genexpression mittels Nukleinsäure-beladener virusähnlicher Partikel |
| AU2017201007B2 (en) * | 2007-10-15 | 2018-12-13 | Sanofi | Antibodies that bind IL-4 and/or IL-13 and their uses |
| EP2050764A1 (en) * | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| EP2220115A2 (en) * | 2007-12-13 | 2010-08-25 | Glaxo Group Limited | Polypeptides, antibody variable domains & antagonists |
| EP2238165B1 (en) * | 2008-01-07 | 2017-07-05 | Government of the United States of America, as represented by the Secretary, Department of Health and Human Services | Anti-hiv domain antibodies and method of making and using same |
| NZ601815A (en) * | 2008-03-31 | 2014-10-31 | Genentech Inc | Compositions and methods for treating and diagnosing asthma |
| CA2721202A1 (en) | 2008-04-17 | 2009-10-22 | Hilde Adi Pierrette Revets | Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same |
| US10407513B2 (en) * | 2008-09-26 | 2019-09-10 | Ucb Biopharma Sprl | Biological products |
| WO2010046337A2 (en) * | 2008-10-21 | 2010-04-29 | Domantis Limited | Ligands that have binding specificity for dc-sign |
| MX2011004550A (es) | 2008-10-31 | 2011-07-20 | Centocor Ortho Biotech Inc | Composiciones de de supercóntigos a base de dominios de fibronectina tipo iii, métodos y usos. |
| CA2744588A1 (en) * | 2008-11-26 | 2010-06-03 | Glaxo Group Limited | Ligands that bind il-13 |
| CA2746395C (en) | 2008-12-10 | 2019-07-09 | Ablynx N.V. | Polypeptides comprising amino acid sequences directed against tie 2 for the treatment of diseases and disorders related to angiogenesis |
| JP5901517B2 (ja) | 2009-05-28 | 2016-04-13 | グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ | 抗原結合性タンパク質 |
| PE20120401A1 (es) * | 2009-05-28 | 2012-05-04 | Glaxo Group Ltd | Proteina de enlace de il-13 |
| WO2011006915A2 (en) * | 2009-07-16 | 2011-01-20 | Glaxo Group Limited | Improved anti-serum albumin binding single variable domains |
| MX2012001278A (es) * | 2009-07-29 | 2012-03-16 | Glaxo Group Ltd | Anticuerpos de dominio simple anti-receptor tgf-beta tipo ii. |
| EP2531523A1 (en) | 2010-02-05 | 2012-12-12 | Ablynx N.V. | Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same |
| SI2533761T1 (sl) * | 2010-02-11 | 2019-08-30 | Ablynx N.V. | Postopki in sestavki za pripravo aerosolov |
| HUE029622T2 (en) | 2010-04-30 | 2017-03-28 | Janssen Biotech Inc | Stabilized fibronectin domain compositions, methods and uses |
| US9150651B2 (en) | 2011-01-06 | 2015-10-06 | Glaxo Group Limited | Single variable domain immunoglobulins that bind TGF-beta receptor II |
| WO2012125775A1 (en) | 2011-03-16 | 2012-09-20 | Sanofi | Uses of a dual v region antibody-like protein |
| US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
| NO2699601T3 (enExample) | 2011-04-21 | 2018-06-16 | ||
| MX358827B (es) | 2011-09-27 | 2018-09-05 | Janssen Biotech Inc | Supercóntigos de proteína basados en repeticiones de fibronectina tipo iii con superficies de unión alternativas. |
| US10481164B2 (en) * | 2012-03-26 | 2019-11-19 | Amgen Inc. | Method for using light scattering in real time to directly monitor and control impurity removal in purification processes |
| SG11201408554QA (en) * | 2012-06-22 | 2015-02-27 | Cytomx Therapeutics Inc | Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof |
| KR102502640B1 (ko) | 2012-08-21 | 2023-02-23 | 사노피 바이오테크놀로지 | Il-4r 길항제의 투여에 의한 천식의 치료 또는 예방 방법 |
| CN113234142B (zh) * | 2012-08-22 | 2024-03-05 | 财团法人牧岩生命工学研究所 | 超稳定免疫球蛋白可变结构域的筛选和改造方法及其应用 |
| US11066467B2 (en) | 2013-12-17 | 2021-07-20 | Mhs Care-Innovation Llc | Compositions and methods for treating ischemic heart disease |
| ES2846099T3 (es) * | 2013-12-17 | 2021-07-28 | Mhs Care Innovation Llc | Composiciones y métodos para tratar la acumulación de tejidos grasos |
| IL315136A (en) * | 2014-02-21 | 2024-10-01 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-4rantagonist |
| WO2015134988A1 (en) | 2014-03-07 | 2015-09-11 | Bristol-Myers Squibb Company | Method of using antibody polypeptides that antagonize cd40 to treat ibd |
| EP3129497B1 (en) | 2014-04-11 | 2021-09-08 | Novartis AG | Methods of selectively treating asthma using il-13 antagonists |
| WO2016055655A1 (en) | 2014-10-10 | 2016-04-14 | Ablynx N.V. | Inhalation device for use in aerosol therapy of respiratory diseases |
| SG11201702688UA (en) | 2014-10-10 | 2017-04-27 | Ablynx Nv | Methods of treating rsv infections |
| CA3246946A1 (en) | 2014-11-14 | 2025-11-29 | Sanofi Biotechnology | Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist |
| AU2015366284B2 (en) | 2014-12-19 | 2021-07-22 | Ablynx N.V. | Cysteine linked nanobody dimers |
| WO2017191108A1 (en) | 2016-05-02 | 2017-11-09 | Ablynx Nv | Treatment of rsv infection |
| JP6293829B2 (ja) * | 2016-08-05 | 2018-03-14 | モガム インスティチュート フォー バイオメディカル リサーチＭＯＧＡＭ Ｉｎｓｔｉｔｕｔｅ ｆｏｒ Ｂｉｏｍｅｄｉｃａｌ Ｒｅｓｅａｒｃｈ | 安定化された免疫グロブリン可変ドメイン選別方法及び選別されたドメインの応用 |
| WO2018099968A1 (en) | 2016-11-29 | 2018-06-07 | Ablynx N.V. | Treatment of infection by respiratory syncytial virus (rsv) |
| WO2018111978A1 (en) | 2016-12-14 | 2018-06-21 | Janssen Biotech, Inc. | Cd137 binding fibronectin type iii domains |
| WO2018111976A1 (en) | 2016-12-14 | 2018-06-21 | Janssen Biotech, Inc. | Pd-l1 binding fibronectin type iii domains |
| KR102568559B1 (ko) | 2016-12-14 | 2023-08-18 | 얀센 바이오테크 인코포레이티드 | Cd8a-결합 섬유결합소 iii형 도메인 |
| US11034768B2 (en) | 2017-10-30 | 2021-06-15 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an IL-4R antagonist |
| CN108855003B (zh) * | 2018-06-28 | 2021-01-05 | 南开大学 | 一种用于清除血液中炎性因子的免疫吸附剂及其制备方法 |
| CN111494626B (zh) | 2018-12-25 | 2022-06-21 | 江苏荃信生物医药股份有限公司 | 用于治疗il-4和/或il-13介导的信号转导相关的疾病的药物组合物 |
| EP3930754A4 (en) * | 2019-02-27 | 2023-08-16 | Zhejiang Nanomab Technology Center Co. Ltd. | HIGH-THROUGHPUT SEQUENCE-BASED PROCEDURE FOR GENERATION OF CAMELID ANTIBODIES TO COVER WIDE EPITOPES WITH HIGH RESOLUTION |
| KR20220034878A (ko) | 2019-07-16 | 2022-03-18 | 사노피 바이오테크놀로지 | Il-4r 길항제를 투여하여 천식을 치료 또는 예방하는 방법 |
| US11781138B2 (en) | 2019-10-14 | 2023-10-10 | Aro Biotherapeutics Company | FN3 domain-siRNA conjugates and uses thereof |
| WO2021076543A1 (en) | 2019-10-14 | 2021-04-22 | Aro Biotherapeutics Company | Epcam binding fibronectin type iii domains |
| CN114786682B (zh) | 2019-10-14 | 2024-07-16 | Aro生物疗法公司 | 结合cd71的纤维粘连蛋白iii型结构域 |
| EP4144758A4 (en) | 2020-04-22 | 2024-05-15 | Mabwell (Shanghai) Bioscience Co., Ltd. | SINGLE VARIABLE DOMAIN ANTIBODY DIRECTED AGAINST HUMAN PROGRAMMED CELL DEATH LIGAND 1 (PD-L1) AND DERIVATIVE THEREOF |
| WO2021226163A2 (en) * | 2020-05-06 | 2021-11-11 | Dragonfly Therapeutics, Inc. | Antibodies targeting clec12a and use thereof |
| AU2021268340A1 (en) | 2020-05-06 | 2022-12-08 | Dragonfly Therapeutics, Inc. | Proteins binding NKG2D, CD16 and CLEC12A |
| JP2024517610A (ja) | 2021-04-14 | 2024-04-23 | アロ・バイオセラピューティクス・カンパニー | Ｃｄ７１に結合するフィブロネクチンｉｉｉ型ドメイン |
| KR20240031947A (ko) | 2021-04-14 | 2024-03-08 | 에이알오 바이오테라퓨틱스 컴패니 | Fn3 도메인-시르나 접합체 및 이의 용도 |
| IL315262A (en) * | 2022-03-03 | 2024-10-01 | Pfizer | Multiple specific antibodies related to IL-4, IL-13 and/or TSLP and their uses |
| JP2025526875A (ja) * | 2022-08-17 | 2025-08-15 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 改善された抗アルブミンナノボディおよびその使用 |
| JP7668943B2 (ja) * | 2023-08-30 | 2025-04-25 | ファイザー・インク | 多重特異性抗体およびその使用 |
| JP7855651B2 (ja) * | 2023-08-30 | 2026-05-08 | ファイザー・インク | 多重特異性抗体およびその使用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5869620A (en) * | 1986-09-02 | 1999-02-09 | Enzon, Inc. | Multivalent antigen-binding proteins |
| US5637481A (en) * | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
| US5863537A (en) * | 1992-02-19 | 1999-01-26 | Schering Corporation | Humanized monoclonal antibodies against human interleukin-4 |
| US6096289A (en) * | 1992-05-06 | 2000-08-01 | Immunomedics, Inc. | Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy |
| US5596072A (en) * | 1992-08-21 | 1997-01-21 | Schering Corporation | Method of refolding human IL-13 |
| GB9511935D0 (en) * | 1995-06-13 | 1995-08-09 | Smithkline Beecham Plc | Novel compound |
| WO2000078334A1 (en) * | 1999-06-17 | 2000-12-28 | University Of Maryland Biotechnology Institute | Chimeric chemokine-antigen polypeptides and uses therefor |
| US7585847B2 (en) * | 2000-02-03 | 2009-09-08 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids for the treatment of asthma and allergy |
| US7175988B2 (en) * | 2001-02-09 | 2007-02-13 | Human Genome Sciences, Inc. | Human G-protein Chemokine Receptor (CCR5) HDGNR10 |
| US6992174B2 (en) * | 2001-03-30 | 2006-01-31 | Emd Lexigen Research Center Corp. | Reducing the immunogenicity of fusion proteins |
| CN1678634A (zh) * | 2002-06-28 | 2005-10-05 | 多曼蒂斯有限公司 | 免疫球蛋白单个变体抗原结合区及其特异性构建体 |
| ES2559763T3 (es) * | 2002-09-10 | 2016-02-15 | Affimed Gmbh | Anticuerpo humano específico de CD3 con propiedades inmunosupresoras |
| CA2511910A1 (en) * | 2002-12-27 | 2004-07-15 | Domantis Limited | Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand |
| GB0407315D0 (en) * | 2003-07-15 | 2004-05-05 | Cambridge Antibody Tech | Human antibody molecules |
| MX361174B (es) * | 2003-12-23 | 2018-11-29 | Genentech Inc | Anticuerpos anti-il13 novedosos y sus usos. |
| WO2005085284A1 (en) * | 2004-02-27 | 2005-09-15 | Regeneron Pharmaceuticals, Inc. | Il-4/il-13 sepecific polypetides and therapeutic uses thereof |
| AR049390A1 (es) * | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
| TWI307630B (en) * | 2004-07-01 | 2009-03-21 | Glaxo Group Ltd | Immunoglobulins |
| JP2008510015A (ja) * | 2004-08-16 | 2008-04-03 | セラヴァンス， インコーポレーテッド | β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有する化合物 |
-
2007
- 2007-01-24 BR BRPI0710572-0A patent/BRPI0710572A2/pt not_active IP Right Cessation
- 2007-01-24 AU AU2007209202A patent/AU2007209202A1/en not_active Abandoned
- 2007-01-24 EA EA200801515A patent/EA200801515A1/ru unknown
- 2007-01-24 CN CNA2007800097556A patent/CN101578298A/zh active Pending
- 2007-01-24 EP EP11157601.3A patent/EP2441838A3/en not_active Withdrawn
- 2007-01-24 TW TW096102774A patent/TW200740843A/zh unknown
- 2007-01-24 CA CA002636854A patent/CA2636854A1/en not_active Abandoned
- 2007-01-24 TW TW096102778A patent/TW200804593A/zh unknown
- 2007-01-24 US US12/223,005 patent/US20110159003A1/en not_active Abandoned
- 2007-01-24 EP EP07705003A patent/EP1976882A2/en not_active Withdrawn
- 2007-01-24 JP JP2008551863A patent/JP2009523459A/ja active Pending
- 2007-01-24 JP JP2008551864A patent/JP2009523460A/ja active Pending
- 2007-01-24 WO PCT/GB2007/000228 patent/WO2007085815A2/en not_active Ceased
- 2007-01-24 KR KR1020087020811A patent/KR20080098382A/ko not_active Ceased
-
2008
- 2008-05-15 US US12/152,903 patent/US20090060916A1/en not_active Abandoned
- 2008-07-02 NO NO20082942A patent/NO20082942L/no not_active Application Discontinuation
- 2008-07-02 IL IL192572A patent/IL192572A0/en unknown
- 2008-07-16 ZA ZA200806202A patent/ZA200806202B/xx unknown
- 2008-07-24 CR CR10179A patent/CR10179A/es unknown
- 2008-07-25 MA MA31143A patent/MA30175B1/fr unknown
-
2009
- 2009-05-13 US US12/992,718 patent/US20120093830A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240124584A1 (en) | Igm fc and j-chain mutations that affect igm serum half-life | |
| CN101445559B (zh) | 三聚体可溶抗体与其产生及使用的方法 | |
| RU2558301C2 (ru) | Полипептиды для связывания с "рецептором конечных продуктов гликирования", а также их композиции и способы, в которых они принимают участие | |
| AU2015357053B2 (en) | Domain-exchanged antibody | |
| TWI588156B (zh) | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 | |
| JP2022512649A (ja) | 三重特異性抗ｃｄ３８、抗ｃｄ２８、および抗ｃｄ３結合タンパク質ならびにウイルス感染を処置するための使用方法 | |
| JP2021121642A (ja) | 二特異性抗体基幹 | |
| EP2050764A1 (en) | Novel polyvalent bispecific antibody format and uses thereof | |
| BR112021006783A2 (pt) | proteína de fusão fc heterodimérica de il-15/r¿ direcionada, composição de ácido nucleico, composição de vetor de expressão, célula hospedeira, e, métodos de produção da proteína de fusão fc heterodimérica de il-15/r¿ direcionada e de tratamento de um câncer. | |
| RU2770209C2 (ru) | Терапевтические антитела против лиганда cd40 | |
| RU2015145719A (ru) | Модифицированные асимметричные антитела, связывающие fc-рецептор, и способы их применения | |
| JP2019502656A (ja) | 改善された血清アルブミン結合性免疫グロブリン可変ドメイン | |
| JP2010532764A5 (enExample) | ||
| TW201803899A (zh) | 三特異性和／或三價結合蛋白 | |
| IL194145A (en) | Transgenic protein heterodimeric regions | |
| JP2020519308A5 (enExample) | ||
| CA2604357A1 (en) | P-cadherin antibodies | |
| JP2009523459A (ja) | 天然の連結部を含有する融合タンパク質 | |
| US20250197481A1 (en) | Antigen Binding Polypeptides, Antigen Binding Polypeptide Complexes and Methods of Use Thereof in HIV | |
| WO2001079494A1 (fr) | Anticorps agonistes | |
| TW202225188A (zh) | 與ｃｄ３結合的多肽構建體 | |
| Park et al. | Generation and characterization of a novel tetravalent bispecific antibody that binds to hepatitis B virus surface antigens | |
| JP2025517120A5 (enExample) | ||
| JP2024523034A5 (enExample) | ||
| WO2024094151A1 (en) | Multi-specific antibody and medical use thereof |